Catalog2 refs
Sermorelin
Growth Hormone SecretagogueGrowth Hormone / IGF-1 AxistherapeuticGHRH Analog | Growth Hormone Releasing HormoneMetabolicGrowth HormoneResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Muscles
Overview
Sermorelin is a 29-amino-acid fragment of human growth hormone-releasing hormone (GHRH) and the shortest piece of GHRH that retains full activity. It binds the GHRH receptor on the anterior pituitary, stimulating the synthesis and pulsatile release of endogenous growth hormone. Because the pituitary remains under somatostatin negative-feedback control, the GH rise is self-limiting, making overdose harder than with recombinant GH. It was FDA-approved in 1990 as a diagnostic for GH deficiency and in 1997 for treating idiopathic GH deficiency in children, but was discontinued commercially in 2008 for business reasons. Off-label and compounded use continues.
Primary Uses
pediatric growth hormone deficiency
anti-aging
body composition improvement
Age-Related GH Decline
Body Composition
Sleep Quality
Bone Density
Diagnosing GH deficiency
GH deficiency testing/support
IGF-1 axis modulation
Body-composition research
Recovery and sleep studies
Diagnosis and treatment of children with idiopathic growth hormone deficiency
Management of adult-onset growth hormone insufficiency
Potential treatment for recurrent glioma
Musculoskeletal injuries and athletic performance research
Lean body mass enhancement
IGF-1 mediated muscle growth
Athletic recovery
Age-related GH decline reversal
Skin quality enhancement
Endogenous GH stimulation
Natural pulsatile secretion maintenance
Growth hormone deficiency treatment
Muscle growth
Fat loss
Growth hormone research
Diagnosis of growth hormone deficiency
Treatment of idiopathic GH deficiency in children with growth failure
Adult anti-aging / age-related GH decline
Stimulation of endogenous growth hormone release
Protocol Reference
Dose
200–250 mcg
Frequency
Once Daily, 2 Hours After Last Meal
Half-life
Approximately 10-20 minutes
Route
Subcutaneous
Evidence
Human Clinical Data Available / Phase 4, FDA Approved / Well Studied / FDA-approved as Geref for growth hormone deficiency / Preclinical (disputed)
Research References· 23
Research Models
HumanRat
Also in Growth Hormone Secretagogue